Catalent, Inc. Common Stock (NY:CTLT)

63.48 UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalent, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)

April 17, 2024

From Robbins LLP

Via Business Wire

Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating ↗

April 12, 2024

BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled...

Via Benzinga

Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings

April 10, 2024

From Robbins LLP

Via GlobeNewswire

Beyond The Numbers: 6 Analysts Discuss Catalent Stock ↗

April 04, 2024

Via Benzinga

(CTLT) - Analyzing Catalent's Short Interest ↗

February 28, 2024

Via Benzinga

In-Depth Examination Of 5 Analyst Recommendations For Catalent ↗

February 20, 2024

Via Benzinga

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics? ↗

March 26, 2024

All three of these high-flying stocks could have more room to run.

Via The Motley Fool

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗

March 23, 2024

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

Via Talk Markets

Did Novo Nordisk Just Get a Jump on Eli Lilly? ↗

March 19, 2024

A recent FDA announcement may have just put one company in the lead.

Via The Motley Fool

The Top 3 Pharma Stocks to Buy in March2024 ↗

March 09, 2024

Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.

Via InvestorPlace

Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug ↗

March 08, 2024

"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late...

Via Benzinga

Earnings Outlook For Catalent ↗

February 08, 2024

Via Benzinga

Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

March 07, 2024

From Catalent, Inc.

Via Business Wire

Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk ↗

March 06, 2024

Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising...

Via Benzinga

Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why ↗

March 05, 2024

Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.

Via The Motley Fool

Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla ↗

March 01, 2024

U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones.

Via Benzinga

Topics ETFs Stocks

Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit) ↗

February 29, 2024

Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.

Via Benzinga

Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors ↗

February 26, 2024

Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.

Via Benzinga

CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT

February 16, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

S&P 500's surge to new highs: Bull trap hiding in plain sight?

February 15, 2024

Nvidia and Meta lead the S&P 500 rally, but there's cause for concern about a potential bull trap amid market volatility and a pivot to stable dividend payers.

Via MarketBeat

Topics ETFs Economy Stocks

Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest? ↗

February 14, 2024

Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures.

Via Benzinga

Topics Stocks

Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs ↗

February 12, 2024

Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market...

Via Benzinga

Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now? ↗

February 11, 2024

Even more revenue is on the way from additional sales of Wegovy.

Via The Motley Fool

Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited ↗

February 10, 2024

Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.

Via The Motley Fool

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

February 09, 2024

From Catalent, Inc.

Via Business Wire

US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March ↗

February 09, 2024

The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory.

Via Benzinga

Earnings Scheduled For February 9, 2024 ↗

February 09, 2024

Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion.

Via Benzinga

The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry ↗

February 08, 2024

Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company.

Via Benzinga

Can financial, healthcare, energy stocks rise as rates stay high?

February 08, 2024

Sectors including financials, healthcare, utilities and energy outperform as interest rates remain high, but some of those industries face challenges in 2024.

Via MarketBeat

Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns ↗

February 07, 2024

Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.